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Background: Chronic Obstructive Pulmonary Disease (COPD) is of increasing importance with about one in four
people estimated to be diagnosed with COPD during their lifetime. None of the existing medications for COPD has
been shown to have much effect on the long-term decline in lung function and there have been few recent
pharmacotherapeutic advances. Identifying preventive interventions that can reduce the frequency and severity of
exacerbations could have important public health benefits. The Warm Homes for Elder New Zealanders study is a
community-based trial, designed to test whether a NZ$500 electricity voucher paid into the electricity account of
older people with COPD, with the expressed aim of enabling them to keep their homes warm, results in reduced
exacerbations and hospitalisation rates. It will also examine whether these subsidies are cost-beneficial.
Methods: Participants had a clinician diagnosis of COPD and had either been hospitalised or taken steroids or
antibiotics for COPD in the previous three years; their median age was 71 years. Participants were recruited from
three communities between 2009 to early 2011. Where possible, participants’ houses were retrofitted with
insulation. After baseline data were received, participants were randomised to either ‘early’ or ‘late’ intervention
groups. The intervention was a voucher of $500 directly credited to the participants’ electricity company account.
Early group participants received the voucher the first winter they were enrolled in the study, late participants
during the second winter. Objective measures included spirometry and indoor temperatures and subjective
measures included questions about participant health and wellbeing, heating, medication and visits to health
professionals. Objective health care usage data included hospitalisation and primary care visits. Assessments of
electricity use were obtained through electricity companies using unique customer numbers.
Discussion: This community trial has successfully enrolled 522 older people with COPD. Baseline data showed that,
despite having a chronic respiratory illness, participants are frequently cold in their houses and economise on
heating.
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Reducing the impacts of chronic diseases is a growing
problem. By 2030, Chronic Obstructive Pulmonary
Disease (COPD) is projected to become the third most
common cause of death globally with about one in four
people estimated to be diagnosed with COPD during
their lifetime [1,2]. The main characteristics include a
progressive, irreversible decline in lung function, accom-
panied by breathlessness, a chronic cough and increased
sputum production. Exacerbations, or acute worsening
of the symptoms, which lead to a decrease in health-
related quality of life, are part of the natural history of
the disease [3]. While smoking is a major cause, there is
a strong social gradient in COPD mortality, independent
of smoking [4,5].
None of the existing medications for COPD has
been shown to have much effect on the long-term
decline in lung function and there have been few
pharmacotherapeutic advances [6]. Identifying pre-
ventive interventions that can reduce the frequency
and severity of exacerbations could have important
public health benefits.
The cost of COPD to society
COPD is a leading reason for admission to hospital,
acute visits to outpatient and emergency departments
and family doctors. It is estimated that about half the
average COPD costs are due to hospitalisation and the
annual hospitalisation costs for a severe COPD patient
are about six times greater than those for a patient with
mild or moderate COPD [7]. National direct and indir-
ect annual costs vary from approximately $US37.2 bil-
lion in an American study [8] to between $A0.8 and
$A1.0 billion per year in an Australian study [9].
In New Zealand, COPD is among the top four major
causes of avoidable hospitalisation, with COPD-related
hospitalisations rising rapidly over the last two decades.
Depending on assumptions about costings and average
length of stay, direct treatment cost estimates range
from $NZ16.4 million in 1998/9 [10], to $NZ102-192
million in 2003 [1].
COPD and housing
A number of studies have linked socio-economic status
(SES) with respiratory illness [11] and specifically COPD
[4,12-15], but few studies have looked at possible links
between housing conditions and exacerbations of COPD.
A review of socio-economic determinants of COPD [16]
looked at home conditions and behaviours, but only one
paper specifically included a housing quality measure
(summarised as years without central heating) which
was significantly inversely related to lung function [17].
Studies relating housing and health often use housing
as a marker for SES, rather than exploring the role ofthe housing itself [18]. In addition, studies that have ex-
amined the role of housing in COPD often use only a
single housing variable. Three studies, using different
housing measures - a composite variable (number of
rooms and sector of landlord) [19]; two binary indicators
of housing quality (presence of central heating and one
or more rooms per person) [4]; and the number of
people living at home [12] -- did not find any observed
relationship with COPD. One set of papers [20,21]
followed COPD patients through an energy efficiency
upgrade; this is reviewed further below.
A review looking at improving life for COPD patients
only mentioned the home in terms of therapies taken
there [22]. Another review found that only one of 171
papers referred to the home environment (temperature)
[23]. Nonetheless, Burge suggests the way forward is
a combination of interventions including warmer
housing [24].
Temperature and respiratory illness
There is a clear association between a cold environment
and morbidity both generally [25] and for people with
COPD [26] during winter in particular [27,28]. COPD
patients who experience frequent exacerbations are
more likely than those with less frequent exacerbations
to acquire a cold, but both groups have approximately
the same rates of COPD exacerbations once the cold has
been acquired [29,30]. Therefore, reducing the risk fac-
tors associated with common winter respiratory diseases
might have a disproportionately advantageous effect on
individuals with COPD.
In New Zealand, the excess winter hospitalisation rate
for COPD is 70% (rate ratio 1.70, 95% CI 1.67, 1.73 for
2000–2004) (Zhang, Viggers et al., submitted). New
Zealand also has a greater seasonality of mortality,
driven by effects on those over 65, than the more ex-
treme climates of the United Kingdom, the United
States, Australia, Japan or Sweden [27,31]. People over
the age of 80 have an approximately 74% increased
chance of dying of respiratory disease in winter rather
than other seasons [31,32]. A study linking census and
mortality data showed an increased risk of dying in
winter among low-income people, those living in rented
accommodation and those living in cities [33]. Such
excess winter mortality also applies to cardiovascular
diseases, but not to non-housing related diseases, such
as cancer. These findings suggest modifying people’s
heating behaviour in winter might result in reduced
rates of illness and possibly mortality.
Temperature of New Zealand homes
Compared to other countries with similar climates,
houses in New Zealand are colder, with an average win-
ter evening living room temperature of 17.9°C and a
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usually the living room, is heated during winter [35].
Average winter overnight bedroom temperatures fall
below 14°C [36], indicating that many bedrooms are
colder than this for all or part of winter.
The World Health Organization included the elderly
in groups vulnerable to low indoor temperatures in the
home, and stated that below 16°C there was a serious
risk to health, and between 16°C and 19°C there were
small risks to health after substantial periods of time
[37]. In England and Wales if people are home all day
acceptable temperatures are defined as 21°C in the main
living area and 18°C in other occupied rooms [38], but
the New Zealand Building Code’s only relevant specifica-
tion is that the interior temperature of old people’s
homes and early childhood centres should be able to be
maintained at a minimum of 16°C [39].
There are suggestions that higher morbidity, as well as
mortality, may be compounded by energy-inefficient or
poorly heated housing, particularly for older people
[40-43]. Research we have previously conducted found
that insulating houses led to a significantly warmer, drier
indoor environment and resulted in improved health
and a trend for fewer hospital admissions for respiratory
conditions [44,45]. The addition of more effective,
sustainable heating, as well as retrofitted insulation, in
houses where there were children with asthma problems,
reduced asthma symptoms, visits to the doctor and
school absences [46].
Fuel poverty and increasing electricity prices
Poorly heated housing is influenced by three factors: the
thermal quality of the house; the income of the occu-
pants; and the price of fuel [47]. Britain has developed
comprehensive policies to address fuel poverty, defined
as households where more than 10% of income must be
spent to achieve adequate temperatures, although that
definition is currently subject to debate [48,49]. Policies
include a universal non-means-tested, non-taxable Win-
ter Fuel Allowance for households containing people
aged over 60, improvement in the quality of social hous-
ing, and energy efficiency measures [38,50].
A model of the effect of the Winter Fuel Allowance
[51] drew on the concept of mental accounting, a term
coined by Thaler to describe models and rules that indi-
viduals use to organise their finances [52,53]. Munro
and colleagues hypothesised that while there was no re-
quirement that the Fuel Allowance would be spent on
fuel bills, there was some evidence that money labelled
as a ‘fuel allowance’ and nominally allocated to this par-
ticular area of expenditure was more likely to be spent
there, so may be an effective way to increase warmth.
Moreover, English households that receive heating and
insulation interventions have shown greater increases inwarmth than those that received insulation interventions
alone [54].
Fuel poverty has been established as an increasing
problem in New Zealand, with potentially 25% of house-
holds meeting this definition in 2008, up from 12% in
2001. With the rising price of energy, its incidence and
severity are increasing [55]. In the last decade, nominal
average retail electricity prices increased over 80% [56],
and real prices by 40%.
The cost of electricity has been rising faster than
inflation-adjusted superannuation leading to particular
difficulties for older people, who may be on fixed in-
comes and lack the physical strength to use fuels such as
wood or wood pellet bags [57]. The use of wood heaters
is also problematic for COPD patients as indoor air pol-
lution can trigger exacerbations [58].
The Ministry of Social Development’s Economic Living
Standard Index, which provides a scale applicable to the
general population, has two items pertinent to fuel pov-
erty: “put up with cold” and “stayed in bed for warmth”
[59]. This underlines that among poorer New Zealanders
domestic warmth is not always affordable.Housing interventions for people with COPD
Possible links have long been made between cold hous-
ing and COPD exacerbations for example, in indoor en-
vironments which are cold with high relative humidity,
mattresses can become very damp and cold [60]. For
people with COPD, maintaining the WHO warmth
guideline of 21°C in living areas for at least nine hours
per day was associated with better health status [20].
Donaldson and colleagues also showed a small increase
in lung function for patients with COPD, when there
was a similar rise in indoor bedroom temperature [26].
Following these associations, Osman and colleagues
conducted a small community trial to investigate the ef-
fect of increasing indoor temperatures on COPD
through home energy improvements. Despite significant
implementation barriers, when the improvements were
made there was an improvement in respiratory health
[21] suggesting a larger trial would be warranted.
Methods/Design
The Warm Homes for Elder New Zealanders (WHEZ)
study is a community-based trial designed to test
whether an electricity voucher paid into the electricity
account of older people with COPD, with the expressed
aim of enabling them to keep their homes warm, results
in reduced exacerbations.
Ethical consent was obtained from the New Zealand
Multi-Region Ethics Committee MEC/07/05/062 and
the Clinical Trial Registration is NCT01627418. Written
informed consent was gained from the participants.
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The primary research question is whether the provision
of an electricity subsidy reduces exacerbations of COPD
requiring hospitalisation, or treatment with corticoste-
roids and/or antibiotics. Secondary questions include
whether the dwelling temperature is affected by the elec-
tricity intervention and whether the estimated benefits
of the intervention exceed the costs.
Intervention
The intervention is a subsidy of NZ $500 (approximately
US $400, £250, €300) towards the household electricity
bill, which was calculated as being sufficient for a
2.4 kW electric heater to run continuously for an add-
itional 10 hours a day for 12 weeks, thus raising the
temperature of one room substantially, as well as the
overall average indoor temperature. The money was paid
directly into the household’s electricity account (in the
first winter of enrolment for the early group, and the
second for the late group). $500 was considered a poten-
tially feasible sum for the government to implement as a
national policy and is comparable to the British Winter
Fuel Subsidy.
The amount was tied to the electricity bill, as
subsidising other common forms of heating, such as
wood or liquefied petroleum gas, would potentially have
a deleterious effect on indoor air quality, which might
adversely affect the participants’ lung function. Initial
feedback on this method of subsidy has been positive;
there have been very few calls to our phone helpline
from people expecting the payment to be made an-
other way.
Due to the complexity of New Zealand’s deregulated
domestic electricity industry, which includes competing
electricity retailers, organising and implementing the
intervention was not a trivial task. However, close liaison
with the electricity companies proved worthwhile and
most were very co-operative. For example, company rep-
resentatives, who understood the study, referred back to
the study team a request from a participant to withdraw
some of the credited money from their account.
Sample size
The primary outcome of concern was the rate of moder-
ate or severe COPD exacerbations amongst the partici-
pants. The TORCH study of combined long-acting beta
agonists and corticosteroids found yearly moderate or
severe exacerbation rates dropped from 1.13 in the
placebo group to 0.85 in the combination therapy group,
giving a rate ratio of 0.75 [61]. The study was sized to
duplicate a reduction of this size – using a negative bi-
nomial model for exacerbation rates as recent analyses
have used these, rather than Poisson models, as the
negative binomial models better account for individualpatient variability [61,62]. A “k” parameter (the shape
parameter of the associated gamma distribution) of 0.46
was used as a reanalysis of the TRISTAN data found this
the most appropriate (95%CI 0.34-0.60) [62]. These pa-
rameters, with a confidence level of 95% and a power of
80% yield an estimated required group size per arm of
239, which allowing for a 15% drop out rate (greater
than the 10% found in the Housing, Insulation and
Health study for the over 65s due to the greater illness
of this study population) suggested an initial sample size
of 550 participants. If the “k” parameter was 0.4 then the
required group size per arm would have been 230, if 0.6
then it would have been 262. If the baseline exacerbation
rate was 1.0 rather than 1.13 then the required group
size per arm would be 260. Therefore 550 participants
was the target sample size.
Recruitment
From 2009 until December 2010, application forms were
distributed through various agencies, including primary
health organisations, COPD support groups, public hos-
pital outpatient departments, and community health
workers. Letters of invitation were also sent to eligible
people discharged after a hospitalisation for COPD.
Concerted attempts were made to follow up incomplete
application forms, so that literacy difficulties did not
automatically disqualify applicants. On receipt of an eli-
gible application form, potential participants were sent
an information sheet, personal consent forms for the
person with COPD and another adult in the household
(optional) and a reply-paid envelope. If the property was
rented, consent forms were included for the landlord to
agree to retrofitter assessment and insulation.
When the signed consent form was returned, the ap-
plicant was sent a letter confirming their acceptance into
the study. Where necessary and feasible, ceiling and
under-floor insulation were upgraded or retrofitted in
homes.
Wave design and randomisation
As winter was the crucial period for the study, and re-
cruitment is often slow at the start of the process the
study was deliberately designed to recruit over two years
in ‘waves’. Participants were recruited from three com-
munities from 2009 to early 2011. Those recruited (i.e.
consent and baseline data received) by June (early winter
in the southern hemisphere) 2010 were assigned to
Wave 1, those recruited later were assigned to Wave 2.
Each wave was randomised into early and late interven-
tion groups – the early group receiving the intervention
the first winter in which the wave was enrolled in the
study, and the late group the following winter. Thus
Wave 1- Early participants received the fuel subsidy dur-
ing 2010; Wave 1- Late and Wave 2- Early participants
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pants received the subsidy during the winter of 2012.
The randomisation was carried out by a statistician ex-
ternal to the study team.
The configuration of an autumn baseline with a spring
follow-up was chosen in recognition of the significant
illness of the sickest participants; with a full winter base-
line there could have been more of a bias towards only
the least unwell people completing the study. We
allowed for a greater drop-out rate than we usually ex-
perience due to the illness among the study population.
As the intervention was carried out at a dwelling level,
in order to avoid clustering, we selected only one pri-
mary participant per household, the person best able to
complete the study questionnaire. The baseline inter-
views were carried out before randomisation so that
knowledge of their group allocation could not affect the
participants’ measures. In order to utilise the voucher
for additional heating, the participants were then in-
formed of their group allocation. Although the inter-
viewers also knew the participant’s group allocation, they
were trained to avoid mentioning group allocation status
during interactions with the participants to minimise
any recall bias. The analyses will be carried out with the
researchers blinded to the meaning of the interventionFigure 1 Flow of participants through the study.group code. We also included several indicators designed
to measure each participant’s propensity to report positive
change and will control for the placebo effect by
conducting sensitivity analyses using these propensity to
positivity scores.
The flow of participants through the study is
summarised in Figure 1, and the wave design portrayed in
Figure 2.
Participants
The demographic characteristics of the 522 COPD par-
ticipants enrolled are presented in Table 1; 20% were
Māori, 77% New Zealand European or European and 2%
Pacific peoples, and 3% reported belonging to other eth-
nic groupings, with only 3% of people reporting more
than one ethnicity. We used the ethnicity classifications
recommended by Statistics New Zealand. We succeeded
in recruiting an older population (median age 71), with
nearly a fifth (18%) of participants being over 80 at
baseline.
Initially the intention was to accept people into the
study whose post-bronchodilator spirometry results
demonstrated GOLD stage II (moderate) COPD or worse
(GOLD, 2005). However, the logistics of conducting high
quality spirometry in the homes of COPD patients created
Figure 2 Study timeline. The wave design and randomisation meant that the interventions were spread over three years.
Table 1 Baseline characteristics of participants
Characteristic % (number)
General health fair or poor 47% (216/460)
Phlegm most days a week 52% (239/458)
Shortness of breath most days a week 62% (288/461)
4 or more bouts of severe chest trouble over winter 22% (99/457)
Able to walk only 100m or less on the flat before stopping for breath 42% (192/457)
At least one cold/flu over winter 65% (294/453)
Ever told have heart disease 47% (210/446)
Ever told have at least 2 of heart disease, cancer, liver disease, renal disease, diabetes, arthritis 42% (179/430)
On home oxygen 8% (39/460)
Received flu vaccine 84% (387/458)
Received pneumonia (pneumococcal) vaccine 22% (96/420)
Lived in dwelling for more than 9 years 63% (290/463)
Dwelling built before 1977 72% (303/422)
Own the dwelling 76% (350/462)
Dwelling always cold 42% (196/462)
Cold at least partly to keep cost of heating down 48% (213/445)
Shivered inside at least once previous winter 56% (249/445)
‘Dragon breath’ inside at least once previous winter 39% (177/450)
Plug in medical equipment 21% (94/454)
Gave “no other choice” as a reason for main form of heating 43% (193/450)
Gave cheap or easy to budget with as reason for main form of heating 29% (129/450)
Eligible for a high use health card* 60% (251/416)
Eligible for community services card ** 77% (337/438)
Receive a disability allowance 51% (220/435)
Currently smoke daily 17% (81/463)
European ethnicity 77% (349/452)
Māori ethnicity 20% (92/452)
Pacific ethnicity 2% (10/452)
Male 50% (228/456)
Aged under 65 27% (122/455)
Aged over 80 18% (81/455)
Median age 71 Years
*This card entitles some frequent users of health services to reduced health co-payments.
** This card entitles people on low income to reduced health (and some other) co-payments.
Viggers et al. BMC Public Health 2013, 13:176 Page 6 of 12
http://www.biomedcentral.com/1471-2458/13/176
Viggers et al. BMC Public Health 2013, 13:176 Page 7 of 12
http://www.biomedcentral.com/1471-2458/13/176a recruitment bottleneck, stalling the study progress. In-
stead, two extra questionsa were added to the application
form to identify people who had suffered a ‘moderate’ or
‘severe’ exacerbation of COPD as defined by the ATS/ERS
Taskforce [63], and were therefore considered at risk of
subsequent exacerbations. Thereafter, those who had been
admitted to hospital for COPD and/or taken steroids or
antibiotics for COPD within the last three years were
considered eligible.
Other essential requirements were for applicants to be
living in the community, in a household responsible for
its own electricity bill, and with the intention of
remaining in the same house for the duration of the
study. In recognition of the earlier onset of COPD mor-
bidity and mortality for Māori, study participants had to
be 55 years of age or older, although applicants of 45 -
years or over were considered if referred on the specific
recommendation of community health workers.
Co-morbidities were not exclusion criteria, unless the
co-morbidities rendered the participant unable to com-
municate effectively. Co-morbidities are to be expected
in this age group and, to be effective, an intervention
must improve COPD in the presence of co-morbidities.
We used a Charlson style index [64-66], modified to be
based on self-report rather than ICD codes, to measure
co-morbidities. Forty-two percent of baseline respon-
dents reported having been told that they had two or
more of: heart disease, cancer, liver disease, renal dis-
ease, diabetes and arthritis; 47% reported heart disease.
Using fuels other than electricity for heating was not
an exclusion criterion, but participants were informed
that only electricity bills would be credited. As we were
attempting to model a possible population–level inter-
vention, we wanted to have as broad inclusion criteria as
feasible.
All participants were encouraged to be vaccinated an-
nually against influenza, but this vaccination had to be
obtained through their own GP or respiratory physician
as part of the standard health-promotion campaigns.
Eighty-four percent of baseline participants reported
having had a flu injection for the most recent flu season
and 22% reported a pneumococcal vaccination in the last
five years.
In 171 households a support person also provided
baseline information. These people completed a short
questionnaire on the burden (if any) of providing care
for the COPD participant, as well as the carer’s general
health.
Setting
The study was set up in three predominantly low-
income urban areas. This study was carried out in part-
nership with local organisations with an interest in
health and housing [44]. These organisations included aMāori health provider, a District Health Board, and Pri-
mary Health Organisations. Two communities were in
the lower North Island (Whanganui and Wellington)
and one in the South Island (Christchurch). Contracts
were negotiated with these providers, who then worked
closely with the research team, employing local field
workers, nurses or community nurses, trained to con-
duct spirometry and administer the questionnaires.
One of the community organisations, Tu Kotahi, a
Māori Asthma and Respiratory provider operating under
the umbrella of Kokiri Marae, a large urban-based
marae (communal meeting place), has participated in
our two previous community housing trials. Our part-
nership is seen as resulting in many positive outcomes
for both parties. For the Tu Kotahi Māori community it
has brought insulated homes, improved heating,
minimising the effects of allergens and increased infor-
mation about healthy housing; for the University re-
searchers it has provided access to the considerable
knowledge of the community, as well as capacity build-
ing for both individual researchers and research groups.
Tu Kotahi’s involvement in housing research projects
has highlighted the effects of poor housing on the health
of their whānau (extended family community). In 2007,
Tu Kotahi established a Māori COPD support programme
and an important aspect has been the focus on healthy
housing. Being research partners in this study has enabled
Tu Kotahi to work more closely with whānau in their
homes to assess their health status prior to, during and
following the winter period, which has brought benefits
beyond the study participation.
“The opportunity to follow up utilising our own com-
munity health worker has been crucial to maintaining
the majority of whānau on the study. We have experi-
enced a transient population during the study and this
has often meant that we have only been able to locate
whānau with information provided by the community
health worker’s networks. Often, we discover that [mem-
bers of the] whānau have been hospitalised or they have
had to travel home for tangihanga (funerals). We also
discovered how socially isolated a number of whānau
are, this sometimes involved numerous visits before the
door was opened for the community health worker to
complete the study questionnaire and tests. We were
also saddened at the number of whānau who passed
away during the study; many of the whānau who partici-
pated experienced other co-morbidities that impacted
on their respiratory conditions.”
The South Island provider, Community and Public
Health, is the public health unit for the region of
Canterbury. Staff also had a well-established working
relationship with the researchers. Since 2001, these staff
also carried out their own local health promotion stra-
tegies connected to housing improvement. Working with
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worthwhile undertaking in terms of developing oppor-
tunities for public health action.
In September 2010 the first of a continuing series of
earthquakes and aftershocks occurred in Christchurch
and the surrounding area [67]. With considerable forti-
tude the Christchurch team did not let the earthquake,
aftershocks or widespread liquefaction disrupt the spring
visits by the field workers. In February 2011 a major
earthquake caused a massive collapse of buildings and
185 lives were lost [68].
Workplaces in the CBD were severely damaged and
the area was closed to the public. The city’s infrastruc-
ture was in chaos as hundreds of organisations and busi-
nesses had no premises to work from, including the staff
of Community and Public Health. This had an impact
on the WHEZ study in a number of ways and the com-
munity researchers set about trying to overcome the
subsequent problems.
Researchers agreed it was necessary to postpone
interviewing for a three-week break to re-establish basic
infrastructure and solve serious logistical problems. Lap-
tops and other research equipment were initially out-of
-bounds in the damaged office and only salvaged much
later; however, the main computer system remained in-
tact and data could be accessed remotely. The re-
searcher’s home served as the research hub for the next
year. There was only minimal disruption to the house-
hold visits when a further round of massive aftershocks
and liquefaction occurred in June 2011. While the
seismic activity has continued, it has diminished in
intensity.
There was damage to the homes of the field workers
and many participants, including chimney damage mak-
ing fireplaces unusable, and structural damage affecting
homes’ weather-tightness. There was also significant
damage to infrastructure such as water, power lines and
sewerage. For instance, because of damaged sewer lines
in her neighbourhood, one field worker had to rely on a
portable toilet on her street front for many months.
Some participants in the WHEZ study vacated their
houses to a safer place for a period of time. Some moved
to the less affected western suburbs or moved out of
Christchurch for a number of weeks until they felt it was
safe to return and this made it difficult for field workers
to track participants down. Driving to the participants’
homes became laborious due to the extensive damage to
roads. The study protocol stating that anyone who
moved could not remain in the study was modified for
the Christchurch participants; because so many other
housing related variables had changed for many of the
participants, there was little point in insisting on address
stability. We also did not think it ethically appropriate to
withdraw the fuel subsidy from participants who wereforced to move because of the earthquake, but were
otherwise keen to continue with the study.
The earthquake and continuous aftershocks were an
emotionally traumatic experience for the participants,
field workers and the co-ordinator. Financial worries
about damaged housing, fear, and uncertainty about per-
sonal safety all contributed to this. The arrival of winter
heightened people’s fears about the adequacy of the
damaged electricity network to supply enough energy
for households to be warm in winter. The field workers
commented on the fears expressed to them during the
research visits. The authorities were contacted for help
in some desperate cases of damaged homes and heaters.
Over the region, 9,000 new heaters were installed in the
homes of people who had lost their primary heat source,
and were paid for by the householder’s insurance
company.
Data collection
Spring and autumn questionnaires
The first main data collection commenced in autumn
(2010 for Wave 1, 2011 for Wave 2). The participants’
basic anthropomorphic measures were collected, spir-
ometry conducted and a health questionnaire completed.
Height was measured using portable stadiometers (Seca
214), and weight with Tanita TIHD316 scales.
Pre- and post- bronchodilator spirometry was carried
out, following ATS/ERS 2005 Task Force Guidelines
[69], using a portable ultrasonic spirometer (Easy One™).
Subjects performed the tests seated. All community
workers were trained to perform spirometry to ATS/ERS
standards. FVC, FEV6, FEV1, PEFR, and FEF25-75 were
recorded. Participants were encouraged to perform three
acceptable manoeuvres, within a maximum of eight at-
tempts. Participants who refused to attempt spirometry
were not excluded from the study. Post-bronchodilator
spirometry was conducted 30 minutes after the adminis-
tration of 400 micrograms salbutamol (VentolinW) via a
VolumaticW spacer.
The questionnaire for the primary participant included
sections on respiratory health, health care usage, general
health, co-morbidities and quality of life, as well as ten-
ure, heating used in the dwelling and house quality.
Similar data, except for height and weight, were col-
lected during subsequent spring and autumn data collec-
tions. One or more data-loggers (HOBO or iButtonW)
monitoring the temperature (and, for a subset of dwell-
ings, humidity) in the dwelling were placed in winter
and collected in spring.
If another adult was living in the dwelling they were
also invited to fill in a shorter ‘support person’ question-
naire, including sections on respiratory health, general
health and the effects on caregivers of caring for the per-
son with COPD on their life.
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Participants were asked to fill in over two-week periods
during summer and winter, a detailed diary asking about
activity, symptoms, medication, and medical care used.
Other data
Objective data on health care usage were found using
participants’ National Health Index (NHI) to access
hospitalisations. Primary care data were obtained from
Primary Healthcare Organisations directly and via the
Healthlink network. Objective assessments of electricity
usage were obtained from electricity companies (Table 2).
Outcome measures
Acceptability of methods The overall feedback from
the majority of the participants in the WHEZ Study has,
to date, been very positive. One such indicative report
from a Wellington interviewer described her assessment
of participants’ experiences in more detail:
“Although at the initial visit some participants had
concerns and were unsure about the study, once they
were given more information and further explanation
of the study then they willingly and happily
participated. In the first year pre-winter visits most of
the participants reported how cold and damp their
homes were and with the escalating cost of electricity
they had to minimize how often they could have the
heaters on to warm their homes. In the post–winter
visit, the first wave of participants that received the
subsidy of $500 commented how grateful and
thankful they were for the subsidy because it helped
tremendously - especially with the high winter
electricity power bills. They also reported on theTable 2 Outcome measures
Primary outcome measure Number of Moderate and severe exacer
Secondary outcome measures A Severe exacerbations of COPD for which
Moderate exacerbations of COPD; define
Hospitalisations for key lower respiratory
All-cause hospitalisation
Temperature in the living and bedroom
Electricity usage
Costs to health care system
Secondary outcome measures-B Self-reported quality of life
Respiratory health of other people living
Any changes in COPD severity (i.e. chan
Study withdrawals due to death or grea
Net benefits (benefits relative to costs) o
Support person burdenchange in warmth in their homes since they had been
insulated.”
Data analysis
Generalised linear models will be fitted to the data. Co-
variates potentially included in the model will be study
arm, current medication, age, sex, region, baseline sever-
ity, smoking status and immunisation status (influenza
and pneumococcal). The appropriateness of a Poisson or
negative binomial model of exacerbations will be con-
firmed by examining the residuals of the observed data
fitted to the postulated models against an envelope of
residuals from a set of simulated trials. If the observed
residuals fall inside the simulated envelope then the
model is considered to fit adequately. A non-parametric
test – rank analysis of covariance – will be used to con-
firm differences between the groups.
Cost-benefit analysis
The design of a cost-benefit analysis of this study is
straightforward and follows similar studies’ methods
[70,71]. The cost side of the intervention follows from
providing a $500 voucher for electricity (and knowing
the amount of electricity actually used). On the be-
nefit side, the principal quantifiable outcome is redu-
ced hospitalisations (ideally, exacerbation-reduced or
exacerbation-free years would be measurable, but this
was beyond the scope of the study). In addition, the
study will estimate and value changes in pharmaceuti-
cal usage.
Discussion
COPD is a growing problem in New Zealand and inter-
nationally, particularly as there are few proven effectivebations of COPD
hospitalisation (ICD-10 code: J44) is required to treat the exacerbation;
d as requiring treatment with systemic corticosteroids and/or antibiotics.
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housing has been linked to respiratory illness, and re-
spiratory infections linked to COPD exacerbations, only
one previous study has directly examined the effect of
indoor temperatures on COPD patients.
Being in a cold house during winter is likely to be a risk
factor for COPD exacerbations. Many New Zealand house-
holds are living in fuel poverty with winter indoor tempera-
tures regarded as unacceptable in other countries. In the
WHEZ study we are addressing the houses’ thermal qualities
and the effective cost of fuel. We have retrofitted insulation
into the houses of vulnerable older people, which we have
previously shown is an effective intervention to reduce fuel
bills and increase the indoor temperature and in this study
we are also subsidising the price of electricity, which indir-
ectly has an impact on disposable household income.
While our intervention is modelled on the age-eligibility
of the British Winter Fuel Allowance (households in which
there is at least one person over 60), it is targeted and only
includes older people who also have a chronic respiratory
illness. In Britain a cash payment is made, whereas our
intervention is paid directly into the participant’s electricity
account and being in the southern hemisphere, these pay-
ments are not made just before Christmas and the holiday
season. These factors make it more likely that the partici-
pants will spend the payment on additional heat.
New Zealand has no income support directly analo-
gous to the Winter Fuel Allowance; however, it does
have a heating supplement available to some people who
receive a disability allowance, but this is only available to
people on low income, who have regular on-going costs,
above those of average people because of their disability
or illness. Due to strict eligibility requirements, it is
often difficult for low-income people to access this bene-
fit and buy extra warmth as indicated by almost half the
vulnerable participants in this study stating that they
were colder than they would have liked because of the
cost of heating; just over half had shivered inside the
previous winter.
The WHEZ study is a staggered intervention community
trial, which does not ‘blind’ the participants as to whether
they are in the intervention or the control group. When
participants were informed that they would be receiving
the fuel subsidy, they were encouraged to see “heat as your
medicine” and provided with sample calculations to help
them estimate how much heating they could use without
overspending the payment. The study is designed to
explore the extent to which this supplement is effective for
helping older people to maintain adequate indoor
environments.
Conclusions
We are successfully implementing a multi-centre,
community-based, randomised control trial in partnershipwith community agencies and primary health organisations
to see whether an electricity voucher enables elderly people
with COPD to better heat their homes, and in turn,
whether this reduces exacerbations of COPD symptoms,
and hospitalisation.
The implementation has been complex and partly
disrupted by a massive seismic event affecting the
Christchurch region. However, the WHEZ study shows
that it is possible to evaluate the merits of targeted wel-
fare benefits for the health of people with chronic and
debilitating diseases such as COPD, for whom an inabil-
ity to keep warm is a common problem.
Endnotes
a When was the last time your COPD got so bad you
needed to go to hospital? and b)When was the last time
your COPD got so bad you needed to take antibiotics or
steroids? The options for both questions were: Never/In
the last year/1-3 years ago/ More than 3 years ago.
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